Multiple ICIs, including antibodies that target programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA4), have been approved for the treatment of a variety of advanced malignancies, including non-small cell lung cancer (NSCLC) (1), skin cutaneous melanoma (SKCM) (2), gastric cancer (3), and bladder urothelial carcinoma (BLCA) (4). This evidence concerns the gene CD274 and bladder transitional cell carcinoma.